Brief: Hcw Biologics Inc Says Masonic Cancer Center Announced First Patient Was Dosed In Phase 1 Clinical Trial To Evaluate HCW9218
19/05/2022 22:40
May 19 (Reuters) - HCW Biologics Inc HCWB.O :
* HCW BIOLOGICS INC - ON MAY 19, MASONIC CANCER CENTER
ANNOUNCED
FIRST PATIENT WAS DOSED IN PHASE 1 CLINICAL TRIAL TO EVALUATE
HCW9218
Further company coverage: HCWB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock
Brief: HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen
Brief: HCW Biologics Prices Private Placement Of 2.8 Mln Units At $1.405 Per Unit
NASDAQ RESUMED AT 09:59 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM